{"id":227297,"date":"2026-09-02T12:09:11","date_gmt":"2026-09-02T06:39:11","guid":{"rendered":"https:\/\/univest.in\/blogs-2\/?p=227297"},"modified":"2026-09-02T12:09:15","modified_gmt":"2026-09-02T06:39:15","slug":"is-alembic-pharmaceuticals-a-good-buy-after-q1-fy27-results","status":"publish","type":"post","link":"https:\/\/univest.in\/blogs-2\/is-alembic-pharmaceuticals-a-good-buy-after-q1-fy27-results\/","title":{"rendered":"Is Alembic Pharmaceuticals a Good Buy After Its Q1 FY27 Results?"},"content":{"rendered":"

Alembic Pharmaceuticals share price around Rs 844. 15.4% below 52-week high of Rs 998. Q1 FY27 revenue Rs 2,165 crore, up 26.1% YoY. PAT Rs 172 crore, up 12.2%. PE 24x.<\/em><\/p>\n

\n

Quick Answer<\/strong><\/p>\n

Alembic Pharmaceuticals’s Q1 FY27 results were broadly steady, with revenue at Rs 2,165 crore and PAT at Rs 172 crore. The Alembic Pharmaceuticals share price near Rs 844 has not moved sharply on this print, and investors asking whether Alembic Pharmaceuticals is a good buy should look at the underlying margin trend rather than the headline numbers alone.<\/p>\n<\/div>\n

The Alembic Pharmaceuticals share price has been under the spotlight this results season after the company reported its first-quarter numbers for FY27. Alembic Pharmaceuticals is a pharmaceutical company with domestic formulations and export generics businesses, and its Q1 FY27 print, for the quarter ended June 30, 2026, gives investors a fresh data point to test whether the stock still deserves a place in a portfolio at current levels.<\/p>\n

Revenue for the quarter came in at Rs 2,165 crore, up 26.1% year on year, while profit after tax came in at Rs 172 crore, up 12.2% from a year earlier. That combination of numbers is exactly what this article breaks down, along with what it means for the Alembic Pharmaceuticals share price from here.<\/p>\n

This piece works through the quarter’s financial highlights, the business factors behind the numbers, where the Alembic Pharmaceuticals share price stands against its 52-week range and valuation multiples, and the key risks worth watching before treating this as a buy, hold or a stock to avoid for now.<\/p>\n

Click Here – Get Free Investment Predictions<\/strong><\/a><\/p>\n

\n
\n

Table of Contents<\/p>\nToggle<\/span><\/path><\/svg><\/svg><\/span><\/span><\/span><\/a><\/span><\/div>\n